In The Pipeline

• SGX Pharmaceuticals has announced that Troxatyl, an investigational drug in a pivotal Phase II/III clinical trial, has been granted fast track designation by the FDA for third-line treatment of acute myeloid leukemia in adults.

• Cerexa has initiated patient enrollment in a Phase II clinical study of PPI-0903, a novel broad-spectrum, next-generation cephalosporin antibiotic with in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA).

• Cardiome Pharma Corp. and its co-development partner Astellas Pharma US have announced the initiation of an open-label safety study of intravenous RSD1235 for the acute treatment of atrial fibrillation.